Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells.

Završnik J, Butinar M, Prebanda MT, Krajnc A, Vidmar R, Fonović M, Grubb A, Turk V, Turk B, Vasiljeva O.

Oncotarget. 2017 Apr 24;8(43):73793-73809. doi: 10.18632/oncotarget.17379. eCollection 2017 Sep 26.

2.

Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin.

Kramer L, Renko M, Završnik J, Turk D, Seeger MA, Vasiljeva O, Grütter MG, Turk V, Turk B.

Theranostics. 2017 Jul 8;7(11):2806-2821. doi: 10.7150/thno.19081. eCollection 2017.

3.

In vivo imaging of protease activity by Probody therapeutic activation.

Wong KR, Menendez E, Craik CS, Kavanaugh WM, Vasiljeva O.

Biochimie. 2016 Mar;122:62-7. doi: 10.1016/j.biochi.2015.11.003. Epub 2015 Nov 4.

4.

Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity.

Mirković B, Markelc B, Butinar M, Mitrović A, Sosič I, Gobec S, Vasiljeva O, Turk B, Čemažar M, Serša G, Kos J.

Oncotarget. 2015 Aug 7;6(22):19027-42.

5.

A role for stefin B (cystatin B) in inflammation and endotoxemia.

Maher K, Jerič Kokelj B, Butinar M, Mikhaylov G, Manček-Keber M, Stoka V, Vasiljeva O, Turk B, Grigoryev SA, Kopitar-Jerala N.

J Biol Chem. 2014 Nov 14;289(46):31736-50. doi: 10.1074/jbc.M114.609396. Epub 2014 Oct 6.

6.

Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor.

Mikhaylov G, Klimpel D, Schaschke N, Mikac U, Vizovisek M, Fonovic M, Turk V, Turk B, Vasiljeva O.

Angew Chem Int Ed Engl. 2014 Sep 15;53(38):10077-81. doi: 10.1002/anie.201402305. Epub 2014 Jun 27.

7.

Decreased IL-10 expression in stefin B-deficient macrophages is regulated by the MAP kinase and STAT-3 signaling pathways.

Maher K, Završnik J, Jerič-Kokelj B, Vasiljeva O, Turk B, Kopitar-Jerala N.

FEBS Lett. 2014 Mar 3;588(5):720-6. doi: 10.1016/j.febslet.2014.01.015. Epub 2014 Jan 23.

8.

Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.

Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, Sagert JG, Hostetter DR, Han F, Gee J, Flandez J, Markham K, Nguyen M, Krimm M, Wong KR, Liu S, Daugherty PS, West JW, Lowman HB.

Sci Transl Med. 2013 Oct 16;5(207):207ra144. doi: 10.1126/scitranslmed.3006682.

9.

Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model.

Butinar M, Prebanda MT, Rajković J, Jerič B, Stoka V, Peters C, Reinheckel T, Krüger A, Turk V, Turk B, Vasiljeva O.

Oncogene. 2014 Jun 26;33(26):3392-400. doi: 10.1038/onc.2013.314. Epub 2013 Aug 19.

PMID:
23955077
10.

The proinflammatory cytokines interleukin-1α and tumor necrosis factor α promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes.

Caglič D, Repnik U, Jedeszko C, Kosec G, Miniejew C, Kindermann M, Vasiljeva O, Turk V, Wendt KU, Sloane BF, Goldring MB, Turk B.

Biol Chem. 2013 Feb;394(2):307-16. doi: 10.1515/hsz-2012-0283.

PMID:
23152404
11.

Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.

Reinheckel T, Peters C, Krüger A, Turk B, Vasiljeva O.

Front Pharmacol. 2012 Jul 11;3:133. doi: 10.3389/fphar.2012.00133. eCollection 2012.

12.

Cysteine cathepsins: from structure, function and regulation to new frontiers.

Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D.

Biochim Biophys Acta. 2012 Jan;1824(1):68-88. doi: 10.1016/j.bbapap.2011.10.002. Epub 2011 Oct 12. Review.

13.

Promising approaches in using magnetic nanoparticles in oncology.

Mikhaylov G, Vasiljeva O.

Biol Chem. 2011 Nov;392(11):955-60. doi: 10.1515/BC.2011.185. Review.

PMID:
21848508
14.

Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment.

Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, Psakhye I, Babes L, Reinheckel T, Peters C, Zeiser R, Bogyo M, Turk V, Psakhye SG, Turk B, Vasiljeva O.

Nat Nanotechnol. 2011 Aug 7;6(9):594-602. doi: 10.1038/nnano.2011.112.

PMID:
21822252
15.

Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice.

Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Müller S, Vasiljeva O, Schwinde A, Klemm N, Deussing J, Peters C, Reinheckel T.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2497-502. doi: 10.1073/pnas.0907240107. Epub 2010 Jan 21.

16.

Autocatalytic processing of procathepsin B is triggered by proenzyme activity.

Pungercar JR, Caglic D, Sajid M, Dolinar M, Vasiljeva O, Pozgan U, Turk D, Bogyo M, Turk V, Turk B.

FEBS J. 2009 Feb;276(3):660-8. doi: 10.1111/j.1742-4658.2008.06815.x.

17.

Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice.

Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Krüger A, Schurigt U, Sevenich L, Turk B, Peters C, Reinheckel T.

Oncogene. 2008 Jul 10;27(30):4191-9. doi: 10.1038/onc.2008.59. Epub 2008 Mar 17.

PMID:
18345026
18.

Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion.

Vasiljeva O, Turk B.

Biochimie. 2008 Feb;90(2):380-6. Epub 2007 Oct 18. Review.

PMID:
17991442
19.

Cell type-specific functions of the lysosomal protease cathepsin L in the heart.

Spira D, Stypmann J, Tobin DJ, Petermann I, Mayer C, Hagemann S, Vasiljeva O, Günther T, Schüle R, Peters C, Reinheckel T.

J Biol Chem. 2007 Dec 21;282(51):37045-52. Epub 2007 Oct 17.

20.

Emerging roles of cysteine cathepsins in disease and their potential as drug targets.

Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B.

Curr Pharm Des. 2007;13(4):387-403. Review.

PMID:
17311556
21.

Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer.

Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, Peters C, Reinheckel T.

Cancer Res. 2006 May 15;66(10):5242-50.

22.

Activation processing of cathepsin H impairs recognition by its propeptide.

Horn M, Dolecková-Maresová L, Rulísek L, Mása M, Vasiljeva O, Turk B, Gan-Erdene T, Baudys M, Mares M.

Biol Chem. 2005 Sep;386(9):941-7.

PMID:
16164419
23.

Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans.

Vasiljeva O, Dolinar M, Pungercar JR, Turk V, Turk B.

FEBS Lett. 2005 Feb 14;579(5):1285-90. Epub 2005 Jan 22.

24.

Recombinant human cathepsin H lacking the mini chain is an endopeptidase.

Vasiljeva O, Dolinar M, Turk V, Turk B.

Biochemistry. 2003 Nov 25;42(46):13522-8.

PMID:
14621998
25.

Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity.

Rozman-Pungercar J, Kopitar-Jerala N, Bogyo M, Turk D, Vasiljeva O, Stefe I, Vandenabeele P, Brömme D, Puizdar V, Fonović M, Trstenjak-Prebanda M, Dolenc I, Turk V, Turk B.

Cell Death Differ. 2003 Aug;10(8):881-8.

26.

Effect of the combined action of flavonoids, ascorbate and alpha-tocopherol on peroxidation of phospholipid liposomes induced by Fe2+ ions.

Vasiljeva OV, Lyubitsky OB, Klebanov GI, Vladimirov YA.

Membr Cell Biol. 2000;14(1):47-56.

PMID:
11051081
27.

Effect of antioxidants on the kinetics of chain lipid peroxidation in liposomes.

Vasiljeva OV, Lyubitsky OB, Klebanov GI, Vladimirov YuA.

Membr Cell Biol. 1998;12(2):223-31.

PMID:
9879545
28.

Immune function in psychogenic depression.

Vasiljeva OA, Kornetov NA, Zhankov AI, Reshetnikov VI.

Am J Psychiatry. 1989 Feb;146(2):284-5. No abstract available.

PMID:
2783542

Supplemental Content

Loading ...
Support Center